Accretion Pharmaceuticals Limited is a high-growth **Contract Development and Manufacturing Organization (CDMO)** and manufacturer of generic and branded formulations. Established in 2012 and headquartered in **Ahmedabad, Gujarat**, the company operates an integrated business model encompassing contract manufacturing, loan licensing, and direct sales. Following its successful **May 2025 IPO**, the company is transitioning from a merchant-export facilitator to a direct global pharmaceutical player with a robust presence in emerging markets. --- ### **Core Business Model & Revenue Architecture** Accretion utilizes a **B2B-focused model**, providing end-to-end manufacturing services for merchant exporters, domestic marketers, and international clients. The company leverages India’s **~20% cost advantage** over China to position itself as a preferred CDMO partner. * **Revenue Mix:** Approximately **70%** of revenue is derived from **export markets**, with the remaining **30%** coming from **domestic contract manufacturing**. * **Service Verticals:** * **CDMO Services:** Specialized outsourced drug development and manufacturing. * **Private Label & Third-Party Manufacturing:** Serving domestic brands and merchant exporters. * **Direct Exports:** Strategic focus on high-growth markets in **Africa, Southeast Asia, and Latin America**. * **Client Ecosystem:** Maintains a network of **165 active clients** and over **70 merchant exporters**. * **Product Authorization:** Authorized to manufacture **1,198 products** offshore. --- ### **Manufacturing Infrastructure & Capacity Utilization** The company operates a state-of-the-art facility in **Ahmedabad** compliant with **WHO-cGMP** and **GLP** standards. Recent IPO-funded upgrades have resulted in a **40% increase in production capacity**. | Segment | Dosage Form Type | Annual Installed Capacity | | :--- | :--- | :--- | | **Tablets** | Solid Orals | **65.0 Crore units** | | **Capsules** | Solid Orals | **20.0 Crore units** | | **Oral Powder** | Bottles & Pouches | **15.0 Crore units** | | **Oral Liquid** | Bottles | **1.8 Crore units** | | **External Preparations** | Tubes (Ointments/Gels) | **0.9 Crore units** | | **Total Capacity** | | **102.7 Crore units** | **Sustainability Integration:** The facility features a **129 KVA rooftop solar power system**, meeting up to **15%** of the plant's energy requirements and reducing long-term operational costs. --- ### **Therapeutic Portfolio & Product Depth** Accretion maintains a broad product mix designed to manage customer portfolios holistically. The company manufactures a wide range of finished dosage forms across several critical therapeutic areas: * **Chronic Care:** Cardiac treatments, Anti-Diabetic, Anti-Hypertensive, and Psychotropic medications. * **Acute Care:** Anti-infectives (Antibiotics, Antifungal), Anti-Malarial, and Gastrointestinal (Antiulcer, Antacid). * **Respiratory & Wellness:** Antihistamines, Antitussives, Vitamins, and Nutritional Supplements. * **Specialized External Preparations:** Medicated shampoos, mouthwashes, dusting powders, and antiseptic gels. * **Consumer Health:** Laxatives, anti-cold preparations, and anti-inflammatory solutions. --- ### **Global Footprint & Regulatory Compliance** Accretion is aggressively expanding its international regulatory footprint to transition toward higher-margin direct sales. * **Geographic Reach:** Direct network spanning **30+ countries** across Africa, Southeast Asia, and Latin America. * **Domestic Presence:** Active in **16 Indian states**, including Gujarat, Maharashtra, Karnataka, and Uttar Pradesh. * **Key Regulatory Approvals:** Holds specific cGMP approvals from authorities in **Cambodia, Rwanda, Nigeria, and Malawi**. * **Strategic Certifications:** * **Quality:** ISO 9001:2015. * **Food Safety:** ISO 22000:2018. * **Environmental:** ISO 14001:2015. * **Operational:** WHO-cGMP and GLP certified infrastructure. --- ### **Financial Performance & Capital Structure** The company has demonstrated significant scaling, highlighted by a **135.59% YoY** revenue surge in **H1 FY26**. | Metric (INR Crore) | H1 FY26 | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | :--- | | **Net Revenue** | **43.74** | **57.38** | **33.67** | | **EBITDA** | **7.07** | **11.92** | **6.92** | | **EBITDA Margin** | **16.17%** | **20.72%** | **20.55%** | | **Profit After Tax (PAT)** | **4.75** | **6.79** | **3.42** | | **ROCE** | **38.11%** | **46.35%** | - | | **Net Debt to Equity** | **0.9** | - | - | **IPO and Liquidity (May 2025):** * Raised **₹29.75 Crore** on the **NSE Emerge** platform (oversubscribed **7.67x**). * **Proceeds Allocation:** Capacity expansion (new equipment), repayment of high-interest borrowings, and funding for international product registrations. * **Working Capital:** Inventory stood at **₹20.61 Crore** in FY25 to meet rising demand, managed via the **FIFO** method. --- ### **Strategic Growth Pillars & Future Outlook** Accretion’s strategy is centered on moving up the value chain through direct market engagement and branded product development. * **Direct Global Engagement:** Shifting away from merchant exporters to direct sales. Currently pursuing plant and product registrations in the **Philippines, Ghana, Rwanda, Nigeria, Cambodia, and Sierra Leone**. * **Branded Portfolio Expansion:** Targeting an increase in branded sales (currently **~10%** of direct exports) to capture higher margins. * **Pipeline Strength:** Over **100 products** are currently in the registration process across international markets. * **Margin Targets:** While H1 FY26 margins were impacted by registration costs, management targets a steady-state EBITDA margin of **20%–22%** as new markets mature. --- ### **Risk Management & Mitigation Framework** The company operates under a structured risk framework to navigate the complexities of the global pharmaceutical landscape. * **Supply Chain Vulnerability:** High dependence on **APIs and KSMs from China**. Mitigation includes **supplier diversification** and strategic bulk sourcing. * **Regulatory & Geopolitical Risks:** Navigating **high US tariffs** and stringent domestic acts (Drugs and Cosmetics Act, 1940). The company focuses on **reshoring manufacturing** and maintaining rigorous **ISO-certified quality controls**. * **Market Concentration:** To mitigate reliance on a small group of clients, the company is expanding its active client base and entering new geographic territories. * **Financial Exposure:** Managing **foreign currency fluctuations** and interest rate changes through disciplined debt repayment and improved credit terms. * **Environmental Compliance:** Adherence to the **Environment (Protection) Act, 1986** and **Bio-Medical Waste Management Rules, 2016** is strictly monitored to prevent operational disruptions.